Methyl B12, or methylcobalamin, is a metabolically active form of vitamin B12 that participates in the methionine synthase pathway. People sometimes use “methyl B12 sensitivity” to describe unwanted symptoms they associate with a methylcobalamin supplement, but that phrase does not identify a single proven genetic or methylation cause.
MTR and MTRR are relevant to B12-dependent one-carbon metabolism. However, a genetic variant does not tell you whether you are “intolerant” to methylcobalamin, whether your current B12 status is adequate, or which B12 form is appropriate for you.
“Methyl B12 sensitivity” is a consumer term commonly used when someone associates unwanted effects with methylcobalamin. It should not be treated as a precise diagnosis or as proof of an MTHFR, MTR, MTRR or COMT problem.
Vitamin B12 biology is more complex than the form printed on a supplement label. Dose, underlying B12 status, health conditions, medications, other ingredients and individual circumstances can all matter when someone reports a reaction.
Short answer: methylcobalamin has a real role in one-carbon metabolism, but current evidence does not support diagnosing “methyl B12 sensitivity” from a single methylation gene or SNP.
Vitamin B12 exists in several chemical forms. Understanding that difference is more useful than dividing supplements into simply “methylated” and “non-methylated.”
Methylcobalamin is one of the metabolically active forms of vitamin B12. It is the B12 form used as an intermediate methyl carrier by methionine synthase.
This makes it directly relevant to the folate/B12 side of one-carbon metabolism.
Adenosylcobalamin is another metabolically active B12 form. Hydroxocobalamin and cyanocobalamin can be converted into active cobalamin forms in the body.
The existence of different forms does not by itself mean one form is universally appropriate or inappropriate for everyone.
Methylcobalamin is closely connected with methionine synthase. This enzyme transfers a methyl group in the remethylation of homocysteine to methionine.
MTR and MTRR have specific biochemical roles in the B12-dependent methionine synthase system. Their roles are more directly relevant than broad claims that any “methylation gene” predicts methylcobalamin tolerance.
MTR encodes methionine synthase. Its B12-binding domain uses methylcobalamin as an intermediate methyl carrier during homocysteine remethylation.
MTRR encodes methionine synthase reductase. It helps restore methionine synthase after the enzyme becomes inactive during normal catalytic cycling.
These genes may be relevant to different parts of one-carbon or methyl-group metabolism, but that does not make them validated tests of methylcobalamin tolerance.
MTR is directly involved in the B12-dependent methionine synthase reaction. A genetic variant still does not measure current enzyme activity or supplement tolerance.
MTRR supports methionine synthase reactivation. An MTRR genotype cannot tell you whether a particular methylcobalamin supplement will cause symptoms.
MTHFR participates in folate metabolism upstream of methionine synthase. MTHFR status is not a direct test for methyl B12 sensitivity.
COMT uses SAM during catechol metabolism. The common idea that COMT genotype alone predicts “methyl donor sensitivity” goes beyond what one genetic result can establish.
AEO answer: no single MTR, MTRR, MTHFR or COMT genotype can reliably tell a person whether they will tolerate methylcobalamin.
Inherited DNA information and current vitamin status answer different questions. A genetic test can identify selected variants, but it does not directly measure whether someone currently has adequate or inadequate vitamin B12.
A reaction that happens after taking a supplement does not automatically identify the biological cause. Several variables can differ at the same time.
A person's underlying vitamin status is different from their inherited genotype and may require separate assessment.
Supplements can differ in B12 form and in their additional ingredients, so the product itself is part of the context.
Folate, B-complex products and other supplements may be used at the same time, making a reaction harder to attribute to one ingredient.
Medication history can be relevant to vitamin B12 status and to the interpretation of symptoms.
Gastrointestinal and absorption issues can affect vitamin B12 status independently of methylation-gene results.
Symptoms attributed to methyl B12 can have other explanations that a consumer genetic report cannot rule in or rule out.
Methylcobalamin participates in a real methyl-transfer pathway, but the phrase “too many methyl groups” is not a precise diagnosis.
The methionine cycle contains multiple connected reactions involving folate, B12, homocysteine, methionine, SAM and many enzymes. A symptom after taking a supplement does not reveal the rate of each of those reactions.
Bottom line: avoid turning terms such as “overmethylated,” “undermethylated” or “methyl donor sensitive” into a diagnosis from symptoms or one SNP. They do not replace clinical assessment of B12 status or other possible explanations.
If your interest in DNA testing began with a reaction to methylcobalamin, review exactly what the test analyzes before purchasing. Do not assume that a general methylation panel can determine supplement tolerance.
MTR, MTRR and vitamin B12 biology do not change by state. For an at-home genetic test, the meaningful U.S. differences are current ordering eligibility, kit delivery, return-shipping logistics and access to appropriate healthcare when nutrient status or symptoms require clinical assessment.
Before ordering, review how DNA methylation testing works, U.S. shipping information and the U.S. testing location guide.
Confirm that the current test includes the specific B12-pathway genes or markers you want to explore.
A consumer DNA report and a clinical vitamin B12 assessment provide different types of information.
Persistent or changing symptoms may require appropriate healthcare evaluation rather than additional interpretation of a genetic report alone.
Use the page that matches the actual question you are researching rather than treating all supplement reactions as the same pathway.
This page separates established vitamin B12 biochemistry from consumer claims about supplement sensitivity and single-SNP predictions.
Direct answers about methylcobalamin, MTR, MTRR, methylation, genetics and vitamin B12 testing.
Methyl B12 is methylcobalamin, one of the metabolically active forms of vitamin B12. It participates in the methionine synthase pathway as an intermediate methyl carrier.
It is commonly used to describe unwanted symptoms someone associates with methylcobalamin. The term does not identify a single established diagnosis or genetic cause.
MTR encodes methionine synthase. This enzyme uses methylcobalamin as an intermediate methyl carrier while transferring a methyl group in the conversion of homocysteine to methionine.
MTRR encodes methionine synthase reductase, which helps restore methionine synthase after it becomes inactive during normal catalytic cycling.
No. MTHFR participates in folate metabolism, but an MTHFR genotype alone cannot predict whether someone will tolerate a methylcobalamin supplement.
COMT uses SAM in catechol metabolism, but a COMT genotype does not by itself establish sensitivity to methylcobalamin or another methyl-containing supplement.
NIH guidance states that current evidence does not show different absorption rates among vitamin B12 supplement forms simply because of the form used.
No. Genetic testing and current vitamin B12 assessment answer different questions. Vitamin B12 status requires appropriate clinical and laboratory information.
A consumer genetic report should not be used by itself to choose a B12 form or determine a supplement or treatment plan.
Scientific context reviewed August 20, 2026. Vitamin B12 evidence, genetic interpretation and current testing specifications should be rechecked as research and products evolve.
If methyl B12 is one reason you are exploring methylation genetics, confirm which MTR, MTRR and related markers are actually included in the current panel and review how the report explains their limitations.
Use genetics for pathway education—not as a stand-alone test of methylcobalamin tolerance.
